Vir Biotechnology SVP sells shares for $14,291
Brent Sabatini, the Senior Vice President and Chief Accounting Officer at Vir Biotechnology, Inc. (NASDAQ:VIR), recently sold 1,562 shares of the company's common stock. According to InvestingPro data ...
Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate
Virpax completed a U.S. Army-backed Probudur study, showing potential for prolonged pain relief and reduced opioid use in surgical recovery.
ICON, a pioneer in the 3D printing of homes, raises $56M led by Norwest, Tiger Global
ICON, which builds homes using 3D printing, has closed on $56 million in Series C funding co-led by Norwest Venture Partners ...
Morgan Stanley Sticks to Their Hold Rating for Blueprint Medicines (BPMC)
Morgan Stanley analyst Michael Ulz maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of ...
Morgan Stanley Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)
Morgan Stanley analyst Michael Ulz maintained a Hold rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $284.00.
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) has received an average recommendation of “Moderate Buy” from the six ratings firms that are covering the stock, Marketbeat reports. One ...